Metformin-Induced Ferroptosis as a Novel Therapeutic Strategy for Cancer

View at publisher Summarise with VIRAT
Authors: Qi Xu, Tengfei Feng, Shuangshuang Wang, Yuxin Shi, Dongyu Hou, Dexuan Zhuang, Yuhe Wei, Jing Guo, Xunwei Wu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a promising target in cancer therapy. Metformin, a widely used antidiabetic drug, has shown potential to induce ferroptosis, offering novel insights into its anticancer mechanisms. Methods: This review summarizes current literature on the molecular mechanisms of metformin-induced ferroptosis, focusing on its regulation of iron metabolism, redox homeostasis, lipid peroxidation, and relevant signaling pathways across different cancer types. Results: Metformin modulates key ferroptosis regulators, including SLC7A11, GPX4, AMPK, NRF2, and ACSL4, thereby promoting intracellular ROS accumulation, GSH depletion, and enhanced lipid peroxidation. Through these effects, metformin enhances ferroptotic sensitivity in multiple cancers and synergizes with ferroptosis inducers, chemotherapy, or radiotherapy to overcome resistance. Discussion: Although metformin shows promise in targeting ferroptosis, several challenges remain, including the heterogeneity of tumor ferroptosis sensitivity, optimal dosing strategies, and the need for reliable biomarkers. Furthermore, the dual roles of some ferroptosis regulators in cancer biology warrant cautious interpretation. Continued research is required to optimize therapeutic combinations and validate preclinical findings in clinical settings. Conclusion: Metformin-induced ferroptosis represents a promising anticancer strategy. Its integration into combination therapies could enhance treatment efficacy and overcome resistance, supporting its clinical repurposing in oncology.

Fields of Study & Subjects

Ferroptosis and cancer prognosis Metabolism Diabetes and Cancer Iron Metabolism and Disorders

Publication details

Journal / source
Anti-Cancer Agents in Medicinal Chemistry
Volume
26
Publication date
17 March 2026
Language
EN